Mirum Pharmaceuticals (MIRM)

NASDAQ:MIRM

MIRM

Mirum Pharmaceuticals

RESEARCH TOOLSreports

Want to see MIRM full AI Analyst Report?

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

749 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$129.78

▲(32.49% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $129.78 with a high forecast of $150.00 and a low forecast of $112.00. The average price target represents a 32.49% change from the last price of $97.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","151":"$151","69.25":"$69.3","96.5":"$96.5","123.75":"$123.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.77777777777777,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,69.25,96.5,123.75,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.62,98.88000000000001,103.14,107.4,111.66,115.92,120.18,124.44,128.7,132.96,137.22,141.48000000000002,145.74,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.62,97.32444444444445,100.02888888888889,102.73333333333333,105.43777777777778,108.14222222222222,110.84666666666666,113.55111111111111,116.25555555555556,118.96,121.66444444444444,124.36888888888888,127.07333333333332,{"y":129.77777777777777,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.62,95.95692307692308,97.29384615384616,98.63076923076923,99.96769230769232,101.30461538461539,102.64153846153846,103.97846153846154,105.31538461538462,106.65230769230769,107.98923076923077,109.32615384615384,110.66307692307693,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$150.00

Average Price Target$129.78

Lowest Price Target$112.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Skorney

Robert W. Baird

$95→$112

Buy

14.34%

Upside

Reiterated

04/28/26

Mirum Pharmaceuticals price target raised to $112 from $95 at BairdMirum Pharmaceuticals price target raised to $112 from $95 at Baird

Swayampakula Ramakanth

H.C. Wainwright

$130→$150

Buy

53.14%

Upside

Reiterated

04/27/26

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. WainwrightMirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

Michael Ulz

Morgan Stanley

$130

Buy

32.72%

Upside

Reiterated

04/20/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), GeneDx Holdings (NASDAQ: WGS) and Agios Pharma (NASDAQ: AGIO)

Joshua Schimmer

Cantor Fitzgerald

$140

Buy

42.93%

Upside

Reiterated

04/09/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Joe Johoon Kim

RBC Capital

$128

Buy

30.68%

Upside

Reiterated

04/07/26

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

Joseph Thome

TD Cowen

$117→$125

Buy

27.62%

Upside

Reiterated

03/27/26

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Mirum Pharmaceuticals (NASDAQ: MIRM) and NovoCure (NASDAQ: NVCR)

Gavin Clark-Gartner

Evercore ISI

$101→$126

Buy

28.64%

Upside

Reiterated

03/04/26

Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISIMirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI

Jonathan Wolleben

Citizens JMP

$140→$132

Buy

34.76%

Upside

Reiterated

02/26/26

Mirum Pharmaceuticals price target lowered to $132 from $140 at CitizensMirum Pharmaceuticals price target lowered to $132 from $140 at Citizens

James Condulis

Stifel Nicolaus

$98→$125

Buy

27.62%

Upside

Reiterated

02/26/26

Mirum Pharmaceuticals price target raised to $125 from $98 at StifelMirum Pharmaceuticals price target raised to $125 from $98 at Stifel

Ryan Deschner

Raymond James

$89.31→$110

Buy

12.30%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), Mirum Pharmaceuticals (NASDAQ: MIRM) and United Therapeutics (NASDAQ: UTHR)

Mani Foroohar

Leerink Partners

$90→$100

Buy

2.09%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Jessica Fye

J.P. Morgan

$53→$77

Buy

-21.39%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

-9.14%

Downside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Skorney

Robert W. Baird

$95→$112

Buy

14.34%

Upside

Reiterated

04/28/26

Mirum Pharmaceuticals price target raised to $112 from $95 at BairdMirum Pharmaceuticals price target raised to $112 from $95 at Baird

Swayampakula Ramakanth

H.C. Wainwright

$130→$150

Buy

53.14%

Upside

Reiterated

04/27/26

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. WainwrightMirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

Michael Ulz

Morgan Stanley

$130

Buy

32.72%

Upside

Reiterated

04/20/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), GeneDx Holdings (NASDAQ: WGS) and Agios Pharma (NASDAQ: AGIO)

Joshua Schimmer

Cantor Fitzgerald

$140

Buy

42.93%

Upside

Reiterated

04/09/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

Joe Johoon Kim

RBC Capital

$128

Buy

30.68%

Upside

Reiterated

04/07/26

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

Joseph Thome

TD Cowen

$117→$125

Buy

27.62%

Upside

Reiterated

03/27/26

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Mirum Pharmaceuticals (NASDAQ: MIRM) and NovoCure (NASDAQ: NVCR)

Gavin Clark-Gartner

Evercore ISI

$101→$126

Buy

28.64%

Upside

Reiterated

03/04/26

Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISIMirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI

Jonathan Wolleben

Citizens JMP

$140→$132

Buy

34.76%

Upside

Reiterated

02/26/26

Mirum Pharmaceuticals price target lowered to $132 from $140 at CitizensMirum Pharmaceuticals price target lowered to $132 from $140 at Citizens

James Condulis

Stifel Nicolaus

$98→$125

Buy

27.62%

Upside

Reiterated

02/26/26

Mirum Pharmaceuticals price target raised to $125 from $98 at StifelMirum Pharmaceuticals price target raised to $125 from $98 at Stifel

Ryan Deschner

Raymond James

$89.31→$110

Buy

12.30%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), Mirum Pharmaceuticals (NASDAQ: MIRM) and United Therapeutics (NASDAQ: UTHR)

Mani Foroohar

Leerink Partners

$90→$100

Buy

2.09%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Jessica Fye

J.P. Morgan

$53→$77

Buy

-21.39%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

-9.14%

Downside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+14.76%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +14.76% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

20/21 ratings generated profit

Average Return

+53.77%

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +53.77% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+129.29%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +129.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 129.78.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.37 with a range of -$0.60 to -$0.14. The previous quarter’s EPS was -$0.10. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $148.79M with a range of $141.00M to $155.10M. The previous quarter’s sales results were $148.93M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is 129.78.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals has 32.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals’s price target?

The average price target for Mirum Pharmaceuticals is 129.78. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $112.00. The average price target represents 32.49% Increase from the current price of $97.95.

What do analysts say about Mirum Pharmaceuticals?

Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Detailed List of Analyst Forecasts